# A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c

> **NCT03048253** · — · UNKNOWN · sponsor: **OrienGene Biotechnology Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** OrienX010

## Key facts

- **NCT ID:** NCT03048253
- **Lead sponsor:** OrienGene Biotechnology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-29
- **Primary completion:** 2017-10-10
- **Final completion:** 2019-10-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03048253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03048253, "A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03048253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*